beta-secretase

beta-secretase

(bā-tă-sē-krĕ-tāz),
Agent that exists in two isoforms; protein with homology to the pepsin family of aspartyl proteases involved in the cleavage of beta-amyloid precursor protein; the gene for this protein is located on chromosome 11.

BACE1

B-site amyloid precursor protein (APP) cleaving enzyme. An aspartic-acid protease encoded by BACE1 on chromosome 11q23.2.-q23.3, which is linked to the pathogenesis of Alzheimer's disease and the formation of myelin sheaths in peripheral nerve cells. BACE1 is a transmembrane aspartic protease (beta-secretase) found in the Golgi apparatus, trans-Golgi network, secretory vesicles, and endosomes. It cleaves amyloid precursor protein (APP) in the brain into amyloid beta peptide, a major component of the amyloid plaques of Alzheimer's disease (AD), the deposition of which is the central pathology in AD, for which BACE1 is potential therapeutic target.
References in periodicals archive ?
Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE.
Beta-secretase isn't the only enzyme that investigators have been chasing as a potential target of Alzheimer's drugs.
Companies to advance beta-secretase (BACE) inhibitors, which hold potential for slowing the progression of this devastating neurodegenerative disease
The company advanced the first beta-secretase inhibitor into the clinic for the treatment of Alzheimer's disease in 2006.
Starting in 1997 researchers started to look for the gene that directs cells to make beta-secretase.
Identification of high affinity beta-secretase inhibitors using fragment-based lead generation (Jeffrey S.
INDIANAPOLIS, July 13, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced results from its non-clinical study in genetically engineered mice examining combination therapy with the murine version of the beta-amyloid antibody N3pG and beta-secretase inhibitor BACE (LY2811376).
to develop products from CoMentis' beta-secretase inhibitor program, including lead compound CTS-21166, which is being developed as a disease-modifying treatment for Alzheimer's disease.
Milestone achieved for BI's initiation of Phase 1 study in beta-secretase (BACE) inhibitor program
Awards were made at a special scientific briefing and luncheon to three scientists who have all individually made significant contributions to the understanding of Alzheimer's by shedding light on beta-secretase and gamma-secretase enzyme activities in the brain - enzymes that play an important role in Alzheimer's disease.
The drug acts by inhibition of beta-secretase (BACE1), one of two enzymes that produce beta-amyloid by breaking down its parent molecule, known as amyloid precursor protein (APP).
The company has two fundamental technology platforms: (i) aspartic protease inhibitors, including beta-secretase inhibitors for Alzheimer's disease; and (ii) nicotinic acetylcholine receptor (nAChR) agonists and antagonists for the treatment of angiogenesis mediated diseases and cognitive disorders.